SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-23-014070
Filing Date
2023-08-09
Accepted
2023-08-09 06:16:53
Documents
57
Period of Report
2023-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q tbph-20230630x10q.htm   iXBRL 10-Q 2125321
2 EX-31.1 tbph-20230630xex31d1.htm EX-31.1 13464
3 EX-31.2 tbph-20230630xex31d2.htm EX-31.2 14241
4 EX-32 tbph-20230630xex32.htm EX-32 16250
  Complete submission text file 0001558370-23-014070.txt   6994118

Data Files

Seq Description Document Type Size
5 EX-101.SCH tbph-20230630.xsd EX-101.SCH 41836
6 EX-101.CAL tbph-20230630_cal.xml EX-101.CAL 54574
7 EX-101.DEF tbph-20230630_def.xml EX-101.DEF 168682
8 EX-101.LAB tbph-20230630_lab.xml EX-101.LAB 378841
9 EX-101.PRE tbph-20230630_pre.xml EX-101.PRE 276115
51 EXTRACTED XBRL INSTANCE DOCUMENT tbph-20230630x10q_htm.xml XML 1092113
Mailing Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104
Business Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104 650-808-6000
Theravance Biopharma, Inc. (Filer) CIK: 0001583107 (see all company filings)

IRS No.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36033 | Film No.: 231153262
SIC: 2834 Pharmaceutical Preparations